Home → Releases → 3 (63) →

MORPHOLOGICAL AND QUANTITATIVE MORPHOMETRIC CHANGES IN THE LIVER IN EXPERIMENTALLY INDUCED METABOLIC SYNDROME

Biological Sciences , UDC: 616.36:616.379-008.64-092.9 DOI: 10.24412/2076-9091-2026-363-129-143

Authors

  • Kurbanova Nodira Navruzovna Uzbekistan Urgench
  • Qadambayev Bekzod Bekpolatovich Uzbekistan Urgench
  • Inoyatova Feruza Khidayatovna Uzbekistan Tashkent
  • Rakhmanov Alisher Khudayberdiyevich Uzbekistan Tashkent
  • Abduvaliyev Abdurakhmon Rustam ogli Uzbekistan Tashkent

Annotation

To study morphological and quantitative morphometric changes in the liver in rats with experimentally induced metabolic syndrome. A histological and morphometric examination of the liver was conducted in animals with a reproduced model of metabolic syndrome. Disorganization of the hepatic lobular structure, macro- and microvesicular steatosis, hepatocyte vacuolization, and moderate mononuclear infiltration were identified. Morphometric analysis demonstrated a statistically significant increase in the area of stea- totic regions and the number of lipid-laden hepatocytes compared with the control group. The findings confirm the development of pronounced structural liver changes and the repro- ducibility of the experimental model.
Tags:
experimental model , liver , metabolic syndrome , morphometry , steatosis

How to link insert

Kurbanova, N. N., Qadambayev, B. B., Inoyatova, F. K., Rakhmanov, A. K. & Abduvaliyev, A. R. (2026). MORPHOLOGICAL AND QUANTITATIVE MORPHOMETRIC CHANGES IN THE LIVER IN EXPERIMENTALLY INDUCED METABOLIC SYNDROME Bulletin of the Moscow City Pedagogical University. Series "Pedagogy and Psychology", 3 (63), 129-143. https://doi.org/10.24412/2076-9091-2026-363-129-143
References
1. 1. Alpízar Salazar M. et al. Natural history of metabolic dysfunction-associated steatotic liver disease: from metabolic syndrome to hepatocellular carcinoma. Medicina. 2025;61(1):88. https://doi.org/10.3390/medicina61010088. EDN: JNOVOB.
2. 2. Bednarz K. et al. The role of GLP-1 receptor agonists in insulin resistance with con- comitant obesity treatment in polycystic ovary syndrome. International Journal of Molecular Sciences. 2022;23(8):4334. https://doi.org/10.3390/ijms23084334. EDN: CICLOX.
3. 3. Bitew Z. W. et al. Magnitude and associated factors of neural tube defects in Ethiopia: a systematic review and meta-analysis. Global Pediatric Health. 2020;7:2333794X20939423. https://doi.org/10.1177/2333794X20939423. EDN: CVYYTC.
4. 4. Chew N. W. S. et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metabolism. 2023;35(3):414–428. e3. https://doi.org/10.1016/j.cmet.2023.02.003. EDN: MNWUDV.
5. 5. Daniele S. M. et al. The eSS rat, a nonobese model of disordered glucose and lipid metabolism and fatty liver. Diabetology & Metabolic Syndrome. 2010;2:15. https://doi. org/10.1186/1758-5996-2-15
6. 6. Giannopoulos C. K. et al. Common pathogenetic pathways of non-alcoholic fatty liver disease and type 2 diabetes mellitus. Current Diabetes Reviews. 2023;19(9):96–114. https://doi.org/10.2174/1573399819666230216112032. EDN: BRKDGC.
7. 7. Guess J., Beltran T. H., Choi Y. S. Prediction of metabolic syndrome in US adults using homeostasis model assessment-insulin resistance. Metabolic Syndrome and Related Disorders. 2023;21(3):156–162. https://doi.org/10.1089/met.2022.0097. EDN: DAQYKG.
8. 8. Herman R. et al. Metformin and insulin resistance: a review of the underlying mecha nisms behind changes in GLUT4-mediated glucose transport. International Jour- nal of Mole cular Sciences. 2022;23(3):1264. https://doi.org/10.3390/ijms23031264. EDN: TEUPRK.
9. 9. Kohira T. et al. Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis. Scientific Reports. 2025;15(1):31982. https://doi.org/10.1038/s41598-025-17396-1. EDN: LMOZDU.
10. 10. Leung A. K. C. et al. Acanthosis nigricans: an updated review. Current Pediat- ric Reviews. 2023;19(1):68–82. https://doi.org/10.2174/1573396318666220429085231. EDN: HHHJFZ.
11. 11. Lund A. et al. Assessment of hepatic steatosis during rat liver regeneration after 70 % par- tial hepatectomy using stereology and MRI-PDFF. Scientific Reports. 2025;15(1):43962. https://doi.org/10.1038/s41598-025-27716-0. EDN: LLJVBN.
12. 12. Manoharan M. P. et al. Obesity and coronary artery disease: an updated sys- tematic review 2022. Cureus. 2022;14(9):e29480. https://doi.org/10.7759/cureus.29480. EDN: BLHUSR.
13. 13. Murali R. et al. Interobserver reproducibility of histologic parameters of melano- ma deposits in sentinel lymph nodes: implications for management of patients with mela- noma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2009;115(21):5026–5037. https://doi.org/10.1002/cncr.24298.
14. 14. Murtha-Lemekhova A. et al. Is metabolic syndrome a risk factor in hepatec- tomy? A meta-analysis with subgroup analysis for histologically confirmed hepatic mani- festations. BMC Medicine. 2022;20(1):47. https://doi.org/10.1186/s12916-022-02239-x. EDN: LTWFKG.
15. 15. Noubiap J. J. et al. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. The Lancet Child & Adolescent Health. 2022;6(3):158–170. https://doi.org/10.1016/S2352- 4642(21)00374-6. EDN: JUMBMJ.
16. 16. Pulatova L. T., Kurbanova N. N. Practical application of chromatographic methods in analyzing the identification of cephalosporin antibiotics. MCU Journal of Natural Scien- ces. 2024;(53):22–35. https://doi.org/10.25688/2076-9091.2024.53.1.02. EDN: YBXNQC. (In Russ.).
17. 17. Russo M. P. et al. Prevalence of diabetes, epidemiological characteristics and vas- cular complications. Archivos de Cardiologia de Mexico. 2023;93(1):30–36. https://doi. org/10.24875/acm.21000410. EDN: FZUAHE.
18. 18. Wong S. K. et al. Biochemical and histopathological assessment of li ver in a rat model of metabolic syndrome induced by high-carbohydrate high-fat diet. Jour- nal of Food Biochemistry. 2020;44(10):e13371. https://doi.org/10.1111/jfbc.13371. EDN: TVVCLM.
19. 19. Yong K. et al. Upfront autologous haematopoietic stem-cell transplantation ver- sus carfilzomib – cyclophosphamide – dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. The Lancet Haematology. 2023;10(2):e93–e106. https://doi.org/10.1016/S2352-3026(22)00350-7. EDN: LWPGYL.
Download file .pdf 1.69 Mb